Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finotonlimab - Sinocelltech

Next Previous
X
Search
Drug Profile

Finotonlimab - Sinocelltech

Alternative Names: Human PD-1 monoclonal antibody - Sinocelltech; SCT-I10; SCT-I10A

Latest Information Update: 10 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Non-small cell lung cancer
  • Phase II/III Liver cancer
  • Phase I Squamous cell cancer
  • No development reported Lymphoma

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase-II/III clinical trial in Liver cancer presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 23 Feb 2023 Sinocelltech terminates a phase III trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in China (IV), due to strategy adjustments, independent of the safety and efficacy of the trial medication (NCT04171284)
  • 15 Jun 2022 Phase-I clinical trials in Squamous cell cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT05552807)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top